ABSTRACT
visual impairment in developed countries 1 . The number of people with AMD in the UK is predicted to increase from 608,000 (2010) to 756,000 (2020) 2 , and in the USA from 10 million (2010) to over 20 million (2050) 3 . AMD is a slowly progressive disease with onset after age 50 years: in the early stages, visual symptoms may be minimal or absent, but in advanced cases, AMD leads to severely reduced visual acuity. This in turn leads to reduced quality of life and independence, with large associated costs to society [4] [5] [6] [7] . Advanced AMD has atrophic and neovascular forms;
while neovascular AMD comprises only around 10% of the disease, it is responsible for over 90% of severe visual loss [8] [9] [10] . The number of people with neovascular AMD in the UK is predicted to increase from 415,000 (2010) to 516,000 (2020) 2 , and in the USA from 1 million (2010) to over 2 million (2050) 3 .
The recent availability of anti-vascular endothelial growth factor (anti- with treatment likely to be required indefinitely 12, 13 . Bevacizumab (Avastin, Genentech Inc./Roche) is a related anti-VEGF drug which is licensed by the FDA for treatment of metastatic colorectal cancer. It has been used widely for AMD 14 Our aims were to analyse national trends in the use of intravitreal injection in England; to report on geographical variation in the introduction of this treatment; and to consider the implications for the NHS. per 100,000 population. HES data are currently unable to distinguish between ranibizumab and bevacizumab injections. Indeed, using code C79.4 alone can not discriminate between intravitreal injection for AMD versus (for example) an antibiotic for infective endophthalmitis.
METHODS

Annual rates of intravitreal injection in
RESULTS
English
We therefore combined the operative code with the diagnostic code for AMD, though it is still possible that a small number of the intravitreal injections for AMD were not anti-VEGF drugs (e.g. corticosteroid adjunct) or were for conditions other than neovascular AMD (e.g. corticosteroid for diabetic maculopathy in a patient with coexisting AMD). This is particularly true where the object of interest is an intervention which involves inpatient admission or day case care. We have also employed means of ensuring that the data have 'face validity', including analysing age-specific data and geographical variation. 
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